Minireviews
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Transplant. Dec 18, 2024; 14(4): 97690
Published online Dec 18, 2024. doi: 10.5500/wjt.v14.i4.97690
New frontiers in retinal transplantation
Francesco Saverio Sorrentino, Patrick Di Terlizzi, Francesco De Rosa, Carlo Salati, Leopoldo Spadea, Caterina Gagliano, Mutali Musa, Marco Zeppieri
Francesco Saverio Sorrentino, Patrick Di Terlizzi, Department of Surgical Sciences, Unit of Ophthalmology, Ospedale Maggiore, Bologna 40100, Italy
Francesco De Rosa, Department of Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori”, Meldola 47014, Italy
Carlo Salati, Marco Zeppieri, Department of Ophthalmology, University Hospital of Udine, Udine 33100, Italy
Leopoldo Spadea, Eye Clinic, Policlinico Umberto I, "Sapienza" University of Rome, Rome 00142, Italy
Caterina Gagliano, Department of Medicine and Surgery, University of Enna "Kore", Enna 94100, Italy
Caterina Gagliano, Eye Clinic, Catania University San Marco Hospital, Catania 95121, Italy
Mutali Musa, Department of Optometry, University of Benin, Benin 300283, Nigeria
Mutali Musa, Department of Ophthalmology, Centre for Sight Africa, Nkpor, Onitsha 434112, Nigeria
Author contributions: Sorrentino FS performed the research, provided the draft, wrote the paper, and provided the final approval of the version of the article; Di Terlizzi P, De Rosa F wrote the outline, assisted in the writing, research, and revisions of the manuscript; Salati C, Spadea L, Musa M and Gagliano C assisted in the research and writing of the manuscript, assisted in the writing and editing of the manuscript; Zeppieri M assisted in the conception, the design of the study, writing, outline, final approval of the version of the article to be published and completed the English and scientific editing.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Marco Zeppieri, MD, PhD, Doctor, Department of Ophthalmology, University Hospital of Udine, p. le S. Maria della Misericordia 15, Udine 33100, Italy. mark.zeppieri@asufc.sanita.fvg.it
Received: June 5, 2024
Revised: July 22, 2024
Accepted: July 24, 2024
Published online: December 18, 2024
Processing time: 106 Days and 22.6 Hours
Abstract

New frontiers about retinal cell transplantation for retinal degenerative diseases start from the idea that acting on stem cells can help regenerate retinal layers and establish new synapses among retinal cells. Deficiency or alterations of synaptic input and neurotrophic factors result in trans-neuronal degeneration of the inner retinal cells. Thus, the disruption of photoreceptors takes place. However, even in advanced forms of retinal degeneration, a good percentage of the ganglion cells and the inner nuclear layer neurons remain intact. This phenomenon provides evidence for obtaining retinal circuitry through the transplantation of photoreceptors into the subretinal region. The eye is regarded as an optimal organ for cell transplantation because of its immunological privilege and the relatively small number of cells collaborating to carry out visual activities. The eyeball's immunological privilege, characterized by the suppression of delayed-type hypersensitivity responses in ocular tissues, is responsible for the low rate of graft rejection in transplant patients. The main discoveries highlight the capacity of embryonic stem cells (ESCs) and induced pluripotent stem cells to regenerate damaged retinal regions. Recent progress has shown significant enhancements in transplant procedures and results. The research also explores the ethical ramifications linked to the utilization of stem cells, emphasizing the ongoing issue surrounding ESCs. The analysis centers on recent breakthroughs, including the fabrication of three-dimensional retinal organoids and the innovation of scaffolding for cell transportation. Moreover, researchers are currently assessing the possibility of CRISPR and other advanced gene editing technologies to enhance the outcomes of retinal transplantation. The widespread use of universally recognized safe surgical and imaging methods enables retinal transplantation and monitoring of transplanted cell growth toward the correct location. Currently, most therapy approaches are in the first phases of development and necessitate further research, including both pre-clinical and clinical trials, to attain favorable visual results for individuals suffering from retinal degenerative illnesses.

Keywords: Retinal transplantation; Retinal stem cell; Human embryonic stem cells; Pluripotent stem cells; Retinal tissue transplant

Core Tip: Current technology using stem cells and grafted tissues is of great interest when dealing with retinopathies. Research has increased in recent decades, but most are still in vitro. Using and manipulating stem cells is not simple and involves many ethical concerns. However, there have been some good outcomes regarding the effectiveness of grafted cells in integrating into degenerated host retinas to restore vision in some form.